Scarica l'app Stockscreener
1.235
4.66%
0.055
Pre-mercato:
1.21
-0.025
-2.02%
Marker Therapeutics Inc Borsa (MRKR) Ultime notizie
Marker Therapeutics (MRKR) to Release Earnings on Monday - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MRKR stock touches 52-week low at $1.35 amid market challenges - Investing.com Australia
MRKR stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR) - Defense World
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga India
Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq
Marker Therapeutics initiated with a Buy at Canaccord - TipRanks
MRKR stock touches 52-week low at $1.45 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.45 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Will Marker Therapeutics Reveal New Clinical Data at Upcoming Cell Therapy Conference? - StockTitan
MRKR stock touches 52-week low at $1.48 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics grants stock options to CEO and directors By Investing.com - Investing.com South Africa
Marker Therapeutics grants stock options to CEO and directors - Investing.com India
Marker Therapeutics (MRKR) Stock Price, News & Analysis - MarketBeat
Analysts Offer Predictions for MRKR FY2024 Earnings - Defense World
Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management - Defense World
Brookline Capital sets $4 target on Marker Therapeutics stock - MSN
MRKR stock touches 52-week low at $1.61 amid market challenges - Investing.com Nigeria
Brookline Capital sets $4 target on Marker Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
MRKR stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 2.8% – Here’s Why - Defense World
Cytokinetics draws new Buy from Citi on aficamten potential - MSN
Biotech Analysis Central Model 10+ Portfolio Pick#16 Marker Therapeutics; MT-601 Lymphoma Data 2nd Half Of 2024, Study Initiation Of OTS MT-401 For AML And Catalysts (NASDAQ:MRKR) - Seeking Alpha
Marker Therapeutics Announces Board Resignation - MSN
MRKR stock touches 52-week low at $1.8 amid market challenges - MSN
Marker Therapeutics Announces Board Resignation By Investing.com - Investing.com Nigeria
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset - MSN
Hematopoietic Stem Cell Transplantation Market: Soaring - openPR
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
MRKR stock touches 52-week low at $2.4 amid challenging year By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next? - Defense World
SEC Form 424B3 filed by Marker Therapeutics Inc. - Quantisnow
BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers - Business Wire
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):